Review the agenda


Femtech innovation, women’s health technology and more

Monday | Tuesday | Wednesday | Thursday | Friday

Monday 11 October


1:1 video meetings - 24hrs across all timezones


Company showcases delivered on-demand 24/7


 

Tuesday 12 October
(All times in BST)


1:1 video meetings - 24hrs across all timezones


Company showcases delivered on-demand 24/7


10:50 LSX Welcome Address


11:00 Panel: Backing The Winners Across The Buregeoning Femtech Innovation Landscape Across Europe And Israel

Often described as more conservative in investment than in the US, in the emerging field of femtech innovation, as part of the boom in healthech more generally, how do investors pick the companies they see as having most potential to make a meaningful impact to women’s health? European investors discuss the wide-ranging innovation coming from across the region, what sort of evidence, data and business models they see as critical to fund a start-up and the importance of a global mindset.

Lucanus Polagnoli, Founder and Managing Partner, Calm/Storm Ventures
Jessica McCreadie, Principal, Octopus Ventures

Lucanus Polagnoli, Co-Founder, CalmStorm Ventures    Jessica McCreadie, Principle, Octopus Ventures


14:00 Panel: Defining Femtech As Its Own Innovative Distinct Market: What’s The Value In A Name?

Predicted to be worth $10 billion globally by 2024, Femtech is seeing increased investment across the board and more attention and focus from healthcare commercial leaders. What are the drivers behind the rise of the industry, and how will it continue to grow? Whether you define yourself as Femtech, or as women’s health technology, why is everyone talking about this, and does the definition actually matter? Leading industry executives discuss the nuances within ‘Femtech’, the growth of the industry and the true value to be realised from this innovation.

  • Distinguishing Femtech, without separating it from the broader health technology space
  • Matching the deal with the investor - if they don’t resonate and understand the problem, will they invest?
  • Helping patients and consumers, whilst building successful businesses: business models, routes to market and revenue streams
  • Creating value within the context of Femtech innovation rather than the concept

Elina Berglund, CEO, Natural Cycles
Lea Von Bidder, Co-Founder and President, Ava Health
Keren Leshem, CEO, Ocon Healthcare
Annemijn Eschauzier, Chief Marketing Officer, Women’s Healthcare GE Healthcare

Elina Berglund, CEO, Natural Cycles    Lea Von Bidder, CEO, Ava-1    Keren Leshem, CEO, OCON Healthcare    Annemijn Eschauzier, CMO, Previously GE Healthcare


16:00 Femtech CEO forum

Open to CEO, Founder, Co-Founder, President, Chairman or c-suite executive (CFO, CBO, CCO, CSO, CMO) of digital first Series A+ funded Femtech company.

Find out more


17:00 Afternoon Keynote Panel: Accelerating US Femtech Investment With A More Holistic View On Women’s Health

Despite femtech’s recent growth and investment pouring into digital health and healthtech, only 3% of the investments in the U.S. since 2011 have focused on women’s health. Of that small percentage, the majority has gone to companies targeting fertility, pregnancy or motherhood. 65% of femtech funding has gone to these areas, with less than 45% of the female population in the U.S. is of reproductive age. Leading US investors in the space discuss how they see the future of the femtech investment landscape, investing in underserved innovation for women’s health and what they look for in investments?

Maria Velissaris, Founding Partner, SteelSky Ventures
Tracy Warren, Managing Partner, Astarte Ventures
Adam Dakin, Managing Director, Dreamit Ventures
Kate Brodock, Founding Partner, W Fund
Christine Brennan, Partner, MRL Ventures Fund LLC
Elizabeth Bailey, Managing Director, Rhia Ventures

Maria Velissaris, Managing Partner, SteelSky Ventures 300x    Tracy Warren, Managing Partner, Astarte Ventures    Adam Dakin, Managing Director, Healthtech, Dreamit Ventures    Kate Brodock, CEO, W Fund    Christine Brennan, Partner, MRL Ventures Fund LLC    Elizabeth Bailey, Managing Director, Rhia Ventures 300x


18:00 Keynote Panel: Big Pharma And Big Medtech – Investment, Partnering And Deal-Making In Femtech And Women’s Health

Whether therapeutic women’s health or new innovations in digital and health technologies, healthcare commercial leaders from big pharma and big medtech are increasingly interested in investment and deals in women’s health. What are the current strategies, and what sort of deals are being sought, be it investments, licencing or partnering pr acquisitions? A panel of healthcare commercial leaders discuss the drivers in the market, their vision for the growth of women’s health, convergence in combining technologies, and what they are looking for in deals.

Caoimhe Vallely-Gilroy, Global Head of Digital Health at Healthcare Business, Merck
Gati Dharani, Director, Innovation Lab, Pfizer
Amy West, Sr. Director, Patient Experience & Digital Health Innovation, Novo Nordisk

Caoimhe Vallely-Gilroy, Global Head of Digital Health at Healthcare Business, Merck    Gati Dharani, Director, Innovation Lab, Pfizer    Amy West, Sr. Director, Patient Experience & Digital Health Innovation, Novo Nordisk


 

Wednesday 13 October
(All times in BST)


1:1 video meetings - 24hrs across all timezones


Company showcases delivered on-demand 24/7


10:50 LSX Welcome Address


11:00 Panel: Impact Investment And CSR In Women’s Health – Addressing Global Challenges

Challenges in women’s health are by no means limited to leading world economies, where much innovation is focussed and there is global unmet medical need. Impact investors have been stepping in to help fund solutions and innovation to address these global women’s health challenges. Investors and corporates companies looking to make a real difference with capital, time, energy and mentorship discuss

Kai Chen, Fund Manager Digital Health and Wellness Fund, TrueNorth Impact
Ann Aerts, Head, Novartis Foundation

Kai Chen, Fund Manager, True North Impact Investments    Ann Aerts, Head, Novartis Foundation


14:00 Afternoon Panel: Key Success Factors In Femtech Fundraising

Medtech and healthtech businesses need significant capital for R&D, to help pass clinical milestones, grow and build out their teams and grow their company. In Femtech, there is the added challenge of education of investors and the lack of VC put into female founders and women-led businesses. Executives of companies who have recently raised significant funding rounds discusses the unique challenges they have faced in securing financing for their businesses, the critical importance of building your investor networks and contacts and how they plan to deploy their capital

Debbie Garner, CEO, Femselect
Rachel Bond, Founder and Chief Executive Officer, Jubel Health
Rachel Braun Scherl, Co-Founder & Managing Partner, SPARK Solutions for Growth
Raoul Scherwitzl, CEO & Co-Founder, Natural Cycles

Debbie Garner, CEO, FEMSelect    Rachel Bond, Founder and CEO, JubelHealth    Rachel Braun Scherl, Co-Founder & Managing Partner, SPARK Solutions for Growth    Raoul Scherwitzl, CEO & Co-Founder, Natural Cycles


16:00 Panel: The Femtech Endorsement Race: Approval, Market Access And Commercialisation

Although the huge benefits of women's health innovation are increasingly being recognised, approval pathways are less defined and there can still be a lack of visibility and communication about about products to patients, consumers and healthcare professionals. Insights into the drivers and motivating factors that increase usage, enhance patient perception, and encourage better engagement will be critical for Femtech to reach its maximum potential. Executives discuss their routes to market, how approval was and can be secured in what can a less defined pathway, and how they are driving commercial success in their organisations.

Anula Jayasuriya, Founder and Managing Director, EXXclaim
Susan Trent, CEO, Atlantic Therapeutics
Giles Hamilton, CEO, ODx Innovations

Anula Jayasuriya, Managing Director, EXXclaim Capital 300x-1    Susan Trent, Senior Vice President and General Manager, Innovo    Giles Hamilton, CEO, ODx Innovations


18:00 Panel: Filling The Gender Data Gap - Navigating Privacy, Education & Innovation

Prior to 1994 and the NIH mandated inclusion of women in clinical trials there were huge missing chunks of research and understanding into women’s health data. Women were simply left out due to concerns that their hormone cycles would bring unwanted complications to trials and the unfounded belief it made no difference if you were treating a man or a woman. Women account for 49.5% of the population, but with significantly less clinical information to develop solutions - closing the data gaps will lead to women being healthier and lower medical costs. Femtech innovators creating the women's healthcare products and those collecting women's health data in trials discuss the challenges in collection and managing data, and the opportunity of this huge untapped and critically important resource.

  • Walking the line between innovation and privacy in women’s health technology?
  • Data security and data access in women’s health
  • Capturing data across large therapeutic areas whilst needing to be captured differently, showing up differently, or be affected by sex-specific factors

Jill Waldner, VP Corporate Strategy and Alliances, Evidation
Ridhi Tariyal, CEO & Co-Founder, NextGen Jane
Eric Dy, Founder and CEO, Bloomlife

Jill Waldner, VP Corporate Strategy and Alliances, Evidation    Ridhi Tariyal, Co-Founder and Chief Executive Officer, NextGen Jane    Eric Dy, Founder and CEO, Bloomlife


 

Thursday 14 October


1:1 video meetings - 24hrs across all timezones


Company showcases delivered on-demand 24/7


 

Friday 15 October


1:1 video meetings - 24hrs across all timezones


Company showcases delivered on-demand 24/7


 

DOWNLOAD BROCHURE